Epiloid's preclinical neurological drug testing is 5 times more predictable with our lab-grown human brain organoids.
Epiloid's preclinical neurological drug testing is 5 times more predictable with our lab-grown human brain organoids.
Epiloid's preclinical neurological drug testing is 5 times more predictable with our lab-grown human brain organoids.
See how our approach reduces drug failures, lowers development costs, and accelerates effective treatments.
See how our approach reduces drug failures, lowers development costs, and accelerates effective treatments.
See how our approach reduces drug failures, lowers development costs, and accelerates effective treatments.
Our Approach
Our Approach
Our Approach
Less than 6% of neurology drugs make it to market
Preclinical models often fail to mimic human brain function, missing key signs of toxicity or drug effectiveness
Every failed candidate can cost $0.8–1.6 billion
Less than 6% of neurology drugs make it to market
Preclinical models often fail to mimic human brain function, missing key signs of toxicity or drug effectiveness
Every failed candidate can cost $0.8–1.6 billion
With Epiloid, drug development is no longer guesswork. It’s informed by human-relevant data from the start.
With Epiloid, drug development is no longer guesswork. It’s informed by human-relevant data from the start.
Our Partners
Our Partners
Our Partners
